Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSOLVE in Diabetic Foot Ulcers
NCT03037970Phase 2Unknown
- Sponsor
- Lynch Biologics
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of becaplermin in diabetic foot ulcer (DFU) (2 arms), sponsored by Lynch Biologics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Successful wound healing for at least two consecutive measurements at Week 12. Status: unknown.
02
Drugs
becaplermin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03037970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03037970.